Sirtris Pharmaceuticals Named as One of the ''Fierce 15'' Biotech Companies of 2007

  
    
  
  
    
      Sirtris Pharmaceuticals (NASDAQ: SIRT), a biopharmaceutical company 
      focused on discovering and developing small molecule drugs to treat 
      diseases of aging such as Type 2 Diabetes, announced today that it has 
      been named to the annual FierceBiotech “Fierce 
      15” list. The complete list of ‘Fierce 
      15’ companies is available in today’s 
      issue of FierceBiotech and on the FierceBiotech Web site at www.fiercebiotech.com.
    
    
      About Sirtris Pharmaceuticals
    
    
      Sirtris Pharmaceuticals is a biopharmaceutical company focused on 
      discovering and developing proprietary, orally available, small molecule 
      drugs with the potential to treat diseases associated with aging, 
      including metabolic diseases such as Type 2 Diabetes. Our drug 
      candidates are designed to mimic certain beneficial health effects of 
      calorie restriction, without requiring a change in eating habits, by 
      activation of sirtuins, a recently discovered class of enzymes that 
      control the aging process. The company's headquarters are in Cambridge, 
      Massachusetts.
    
    
      This press release contains forward-looking statements within the 
      meaning of the Private Securities Litigation Reform Act of 1995 
      concerning Sirtris Pharmaceuticals, its product candidates, and those 
      candidates' clinical potential. These forward-looking statements about 
      future expectations, plans and prospects of Sirtris Pharmaceuticals 
      involve significant risks, uncertainties and assumptions, including 
      risks related to the lack of results that would provide a basis for 
      predicting whether any of the Company’s 
      product candidates will be safe or effective, or receive regulatory 
      approval, the Company's potential inability to initiate and complete 
      preclinical studies and clinical trials for its product candidates, the 
      fact that none of the Company's product candidates has received 
      regulatory approvals, the potential inability of the Company to gain 
      market acceptance of the Company's product candidates, and those other 
      risks factors that can be found in the Company's filings with the 
      Securities and Exchange Commission. Actual results may differ materially 
      from those Sirtris Pharmaceuticals contemplated by these forward-looking 
      statements. Sirtris Pharmaceuticals does not undertake to update any of 
      these forward-looking statements to reflect a change in its views or 
      events or circumstances that occur after the date of this release.